RxDoctor Payments Data

Ankur Patel, DO

Pain Medicine · Gainesville, GANPI 1780971994

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $15,261 of the $21,388 with a category attached, or 71.4%. 41 manufacturers reported payments, led by Medtronic at 25.0% of the total. Reporting peaked in 2023 at $6,151 and has fallen 73.8% since, to $1,614 in 2025. Among pain medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,388in general payments, 2019–2025

Across 323 payments — averaging $66.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$4K
  • Saluda Medical Americas, Inc.$3K
  • Boston Scientific$3K
  • Nevro Corp.$1K
  • Stimwave Technologies Incorporated$914
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$5,65426%
  • Food & beverage$15,26171%
  • Education$4732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,388 in reported general payments places this provider in the 95th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$84,182
Medicare patients
204
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate49$29,392
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen808$24,677
Buprenorphine63$20,247
BelbucaBuprenorphine Hcl19$17,016
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen612$15,057
MovantikNaloxegol Oxalate16$6,497
Pregabalin146$6,369
Oxycodone Hcl292$5,793
Fentanyl27$4,985
Gabapentin318$4,181
Morphine Sulfate ErMorphine Sulfate124$2,374
Tizanidine Hcl236$2,262
Tramadol Hcl ErTramadol Hcl37$2,143
Lidocaine28$1,745
Methocarbamol68$839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$108$46,40768 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →